Layoffs
GlaxoSmithKline CEO Emma Walmsley is not done reshaping her leadership team as she continues to overhaul the company’s pharmaceutical division.
Cellectar Biosciences is closing its manufacturing operations and contracting them out.
As a result, the company will cut 300 jobs, primarily in Massachusetts and Connecticut.
Not only has the company made changes to its R&D division, it is strengthening its sales division as well.
About 200 of the job cuts will be in Massachusetts, the remaining in Connecticut.
The company will undergo a reorganization that includes the termination of a number of sales representatives.
The agreement covers employees who agree to leave voluntarily.
Allergan will cut about 5 percent of its workforce, as the company looks to cut costs due to increased pipeline competition and loss of exclusivity on some products.
OvaScience provided a corporate update that includes initial data from a Phase I trial and news of extensive layoffs.
The company’s sales department will take the brunt of the layoffs, losing 235 jobs.
PRESS RELEASES
